Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update
February 8, 2021 4:05 PM ESTFinancial Highlights, 2021 Revenue Guidance and Legal Update
Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019Preliminary fourth quarter revenue $85.7 million, compared to $87.9 million in fourth quarter 20192021 revenue guidance $375 - 405 millionPreliminary 2020 fully diluted GAAP net income $0.85 per share, compared to $0.77 per share in 2019Preliminary fourth quarter fully diluted GAAP net income $0.20 per share, compared to $0.24 per share in fourth quarter 2019Preliminary cash and investments at December 31, 2020 of $476.9 million, an increase of $161.6 million from December 31, 2019Patent Trial and Appeals Board... More